anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a medicine ointment for treating myocardial infarction. The poultice of the invention is an external-use compound paste preparation which is refined by main 11 drugs as effective ingredients; the drugs contain Pollen Typhae, Radix Paeoniae Alba, Fructus Trichosanthis, Ramulus Cinnamomi, Rhizoma Pinelliae, Semen Persicae,  Flos Carthami, Faeces Trogopterori, Radix Notoginseng and Succinum. The invention has evident effect on treating thrombus and myocardial infarction. The paste body of the poultice is fine, soft and smooth, easy to be coated on cloth and uneasy to melt, easy for carrying and using because of small size and good for quick recovery of the focuses. The poultice has stable drug property and has the characteristics of quick percutaneous absorption, good ventilation property and gradual drug releasing. Compared with the oral preparation, the invention has the advantages of no liver-intestines first-filter action, no influence from gastrointestinal degradation and high bioavailability. Compared with injection, the invention has the advantages of convenient use and no pain. Compared with ointment, the invention has the advantages of accurate dose and fixed absorption area. Compared with black plaster and sticking plaster, the invention has the advantages of no sensibility on skin, no pollution to clothes, long effect, percutaneous absorption and convenient carrying and use.
The three groups will receive RPWT with the device BTL-6000 Radial Shockwave Therapy (BTL Industries, Ltd.). Each patient, in supine position and knee flexion of 30 to 60 degrees, will receive 3 sessions of RPW, once per week, 2,000 impulses per session, 2.0 bar and frequency of 10Hz. The air pressure and frequency will be adjusted in response to discomfort. The control group will receive 1,000 pulses at the two most painful sites of the treated knee, in accordance with the technique employed in the majority of previous studies in this field.
To investigate the repeatability of MRI assessment, 10 development phase healthy volunteers will be recruited to undergo two repeated study assessments. The second visit will be between 7 and 14 days after their first visit. The second repeated study assessment will follow the same procedure as the first visit, consisting of blood glucose assessment and MRI assessment. Participants will be advised to fast from mid-night and avoid eating breakfast.
Vasodilation in response to low oxygen (O2) tension (hypoxic vasodilation) is an essential homeostatic response of systemic arteries that facilitates O2 supply to tissues according to demand. However, how blood vessels react to O2 deficiency is not well understood. A common belief is that arterial myocytes are O2-sensitive. Supporting this concept, it has been shown that the activity of myocyte L-type Ca2+channels, the main ion channels responsible for vascular contractility, is reversibly inhibited by hypoxia, although the underlying molecular mechanisms have remained elusive. Here, we show that genetic or pharmacological disruption of mitochondrial electron transport selectively abolishes O2 modulation of Ca2+ channels and hypoxic vasodilation. Mitochondria function as O2 sensors and effectors that signal myocyte Ca2+ channels due to constitutive Hif1α-mediated expression of specific electron transport subunit isoforms. These findings reveal the acute O2-sensing mechanisms of vascular cells and may guide new developments in vascular pharmacology.
The investigators will perform two applications of 40s of continuous Theta Burst Stimulation (cTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left motor cortex will be determined by Localite Neuronavigation. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
The active control group will receive usual care, i.e. PCP provides obesity management using decision support tools in the electronic health record and refers to a tertiary care program at the academic center. This program is the traditional family-based behavioral weight control program which consists of 20 one-hour, group-based sessions over 6 months.
INTRODUCTION: The durability of hemodialysis vascular access remains a troublesome issue for the patients as well as vascular surgeons that requires frequent reinterventions to maintain the access function.
AIM: This study aimed to evaluate straight thigh polytetrafluethylene (PTFE) arteriovenous graft (AVG) in patients with exhausted upper extremities dialysis access.
METHOD: Our study was a retrospective analysis of prospectively collected data of 30 patients were operated upon for straight pattern lateral thigh PTFE AVG between 2016 and 2018. The primary outcome was efficacy and patency of AVG, and secondary outcome was procedure safety, including infection, thrombosis, ligation, lower limb functional status, and mortality.
RESULTS: A 30 patients with 30 Lower Limb AVG with maximum 30-month follow-up period. The mean age was 48 years. Males were (n = 15/30). Thrombophilia patients were (n = 7/30). Primary patency at 6 months was 100%. It declined to 93% at 12 months, 73% at 18 months, 47% at 24 months, and 40% at 30 months. The secondary patency was 97% at 18 months, 83% at 24 months, and 73% at 30 months. More than half of the patients showed complications (n = 18/30), the most frequent was thrombosis (n = 16/18). A secondary procedure was needed for 17 patients, the most frequent was thrombectomy (n = 11/17), adjunctive culprit lesion repair was the key for regaining graft patency. Graft removal was necessary in six patients due to infection (n = 4) and ruptured graft aneurysm (n = 2).
CONCLUSION: Lateral straight thigh PTFE AVG is a reliable and durable alternative modality with adequate dialysis efficacy in patients with exhausted upper extremities dialysis accesses. Secondary procedures due to complications were frequent but no significant major bleeding as regard patients with ruptured graft were non-significant and no distal threatening ischemia or related deaths were observed.
Dizziness, drowsiness, and dry mouth have been reported with fexofenadine hydrochloride overdose. Single doses of fexofenadine hydrochloride up to 800 mg (6 healthy subjects at this dose level), and doses up to 690 mg twice daily for 1 month (3 healthy subjects at this dose level) or 240 mg once daily for 1 year (234 healthy subjects at this dose level) were administered without the development of clinically significant adverse events as compared to placebo. 

In the event of overdose, consider standard measures to remove any unabsorbed drug. Symptomatic and supportive treatment is recommended. Following administration of terfenadine, hemodialysis did not effectively remove fexofenadine, the major active metabolite of terfenadine, from blood (up to 1.7% removed). 

No deaths occurred at oral doses of fexofenadine hydrochloride up to 5000 mg/kg in mice (110 times the maximum recommended daily oral dose in adults and children based on mg/m2) and up to 5000 mg/kg in rats (230 times the maximum recommended daily oral dose in adults and 210 times the maximum recommended daily oral dose in children based on mg/m2). Additionally, no clinical signs of toxicity or gross pathological findings were observed. In dogs, no evidence of toxicity was observed at oral doses up to 2000 mg/kg (300 times the maximum recommended daily oral dose in adults and 280 times the maximum recommended daily oral dose in children based on mg/m2).
Coloured soaps, paints and enamels are protected from deterioration in sunlight by including therein an ultra-violet light absorber of the general formula:- <FORM:0786762/III/1> wherein R and R1 are hydrogen or alkyl groups such as methyl, ethyl, propyl, butyl, amyl, hexyl, heptyl, octyl, octadecyl or lauryl.  Dyestuffs specified for inclusion in soaps are Ultramarine Blue, Methyl Violets, Alizarine or naphthol compounds of chlorophyll, Chrysoidine, diazamine compounds, paramine compounds, Bismuth brown and Saffranine.  The soaps also may contain germicidal or bactericidal compounds.  U.S.A. Specification 2,686,812 is referred to.  Reference has been directed by the Comptroller to Specification 706,151, [Group IV (a)].ALSO:Coloured cellulose ether or cellulose ester dopes are protected from the effects of ultraviolet light by including therein a solution of a compound of the general formula <FORM:0786762/IV (a)/1> wherein R and R1 may be hydrogen or alkyl groups such as methyl, ethyl, propyl, butyl, amyl, hexyl, heptyl, octyl, octadecyl or lauryl. U.S.A. Specification 2,686,812 is referred to.  Reference has been directed by the Comptroller to Specification 706,151.ALSO:Rubber compositions such as india rubber, balata and gutta percha, and synthetic products such as polychloroprene, olefin polysulphides, polybutadiene, butadiene-styrene copolymers such as Buna S and butadiene-acrylonitrile copolymers such as Buna N, are stabilized against the effects of ultra-violet light by incorporating therein a compound of the general formula:  <FORM:0786762/V/1> wherein R and R1 are hydrogen or alkyl groups such as methyl, ethyl, propyl, butyl, amyl, hexyl, heptyl, octyl, octadecyl or lauryl.  U.S.A. Specification 2,686,812 is referred to.  Reference has been directed by the Comptroller to Specification 706,151 [Group IV(a)].ALSO:Coloured bath salts are stabilized against the effects of ultra-violet light by including therein a compound of the general formula <FORM:0786762/VI/1> wherein R and R1 are hydrogen or alkyl groups such as methyl, ethyl, propyl, butyl, amyl, hexyl, heptyl, octyl, octadecyl or lauryl.  Dyestuffs added to the salts may be Auramine, Acridine orange, Chrysine, Phenylene brown, Methylene blues and basic greens.  U.S.A. Specification 2,686,812 is referred to. Reference has been directed by the Comptroller to Specification 706,151, [Group IV (a)].
Citicoline, a compound produced naturally in small amounts in the human body, assumes a pivotal role in phosphatidylcholine synthesis, a dynamic constituent of membranes of neurons. Across diverse models of brain injury and neurodegeneration, citicoline has demonstrated its potential through neuroprotective and anti-inflammatory effects. This review aims to elucidate citicoline's anti-inflammatory mechanism and its clinical implications in conditions such as ischemic stroke, head trauma, glaucoma, and age-associated memory impairment. Citicoline's anti-inflammatory prowess is rooted in its ability to stabilize cellular membranes, thereby curbing the excessive release of glutamate-a pro-inflammatory neurotransmitter. Moreover, it actively diminishes free radicals and inflammatory cytokines productions, which could otherwise harm neurons and incite neuroinflammation. It also exhibits the potential to modulate microglia activity, the brain's resident immune cells, and hinder the activation of NF-κB, a transcription factor governing inflammatory genes. Clinical trials have subjected citicoline to rigorous scrutiny in patients grappling with acute ischemic stroke, head trauma, glaucoma, and age-related memory impairment. While findings from these trials are mixed, numerous studies suggest that citicoline could confer improvements in neurological function, disability reduction, expedited recovery, and cognitive decline prevention within these cohorts. Additionally, citicoline boasts a favorable safety profile and high tolerability. In summary, citicoline stands as a promising agent, wielding both neuroprotective and anti-inflammatory potential across a spectrum of neurological conditions. However, further research is imperative to delineate the optimal dosage, treatment duration, and underlying mechanisms. Moreover, identifying specific patient subgroups most likely to reap the benefits of citicoline as a new therapy remains a critical avenue for exploration.
In the dynamic landscape of maternal and child health, understanding the intricate interplay between environmental factors and pregnancy outcomes is of paramount importance. This study investigates the relationship between maternal greenness exposure and preterm births in Brazil using data spanning from 2010 to 2019. Satellite-derived indices, including the Normalized Difference Vegetation Index (NDVI) and Enhanced Vegetation Index (EVI), were employed to assess greenness exposure during whole pregnancy in maternal residential area. Employing Cox proportional hazard models, we calculated the hazard ratios (HRs) with 95% confidence intervals (CIs) for changes in NDVI, while adjusting for individual and area-level covariates. In total, 24,010,250 live births were included. Prevalence of preterm birth was 11.5%, with a modest but statistically significant decreasing trend (p = 0.013) observed across the nation over the study period. The findings reveal a significant association between greenness exposure and a reduced risk of preterm birth. Specifically, for every 0.1 increase in NDVI, there was a 2.0% decrease in the risk of preterm birth (95%CI: 1.9%-2.2%). Stratified analyses based on maternal education and ethnicity indicated potential effect modifications, with stronger protective effects observed among younger mothers and those with less years of education. Sensitivity analyses using EVI yielded consistent results. In conclusion, this study suggests that higher maternal greenness exposure is linked to a decreased risk of preterm birth in Brazil. These findings imply that enhancing residential greenspaces could be a valuable public health strategy to promote maternal and child health in Brazil.
Each subject will receive a topical application of 0.2 mL of Petrolatum under semi-occlusive patch conditions OD for 21 days. This will serve as a negative control.
The present invention provides novel means and methods for eliminating unwanted cells or organisms from a (mammalian) subject. In particular tumors can be combatted using the compositions according to the present invention. In a preferred embodiment solid tumors are injected with a burst of cytokine (in particular IL-1a or IL-3) together with a slow release source for a cytokine. To further boost the immune system an adjuvans is preferred. In a preferred embodiment the source for the slow release cytokine is a recombinant adenovirus. In an especially preferred embodiment the adjuvant comprises inactivated (cracked) adenovirus producing cells.
Denture adhesive are materials used to reduce the displcament of the mandibular and maxillary dentures during mastication and speech. It provides a sense of security and confidence for denture wearers. More importantly, it facilitates people suffering from dry mouth, hypofunction of their salivary glands and unfavourable jaw ridges in wearing their dentures. In the Philippines, a third world country with 7,100 islands, denture adhesives are considered expensive. Its availability and accessibility to the public posed a proble. The researchers seek to look into the vast natural resource of the Philippines that would function as denture adhesive. Okra is a popular vegetable but little is known about its other uses specially its mucilage property. Mucilage means glue-like. This awakened the interest of the researchers to study on the mucilage property of Okra.
Participants will receive dose-volume equivalent placebo IV infusions for both 3BNC117-LS-J and 10-1074-LS-J at Step 1 entry (Day 0). Participants will discontinue ART on Day 2.
BACKGROUND: Facilitating the healing process of injured anterior cruciate ligament (ACL) tissue is crucial for patients to safely return to sports. Stem cell derived exosomes have shown positive effects on enhancing the regeneration of injured tendons/ligaments. However, clinical application of exosomes in terms of storage and pre-assembly is challenging. We hypothesized that lyophilized exosomes derived from human umbilical cord stem cells (hUSC-EX) could enhance the cell activity of chronically injured ACL cells.
MATERIALS AND METHODS: We harvested the 8 weeks injured ACL cells from rabbit under IACUC (No. 110232) approval. The studied exosomes were purified from the culture medium of human umbilical cord stem cells (IRB approval No. A202205014), lyophilized to store, and hydrated for use. We compared exosome treated cells with non-exosome treated cells (control group) from the same rabbits. We examined the cell viability, proliferation, migration capability and gene expression of type I and III collagen, TGFβ, VEGF, and tenogenesis in the 8 weeks injured ACL cells after hUSC-EX treatment.
RESULTS: After hydration, the average size of hUSC-EX was 84.5 ± 70.6 nm, and the cells tested positive for the Alix, TSG101, CD9, CD63, and CD81 proteins but negative for the α-Tubulin protein. After 24 h of treatment, hUSC-EX significantly improved the cell viability, proliferation and migration capability of 8 weeks injured ACL cells compared to that of no exosome treatment group. In addition, the expression of collagen synthesis, TGFβ, VEGF, and tenogenesis gene were all significantly increased in the 8 weeks injured ACL cells after 24 h hUSC-EX delivery.
DISCUSSION: Lyophilized exosomes are easily stored and readily usable after hydration, thereby preserving their characteristic properties. Treatment with lyophilized hUSC-EX improved the activity and gene expression of 8 weeks injured ACL cells.
CONCLUSION: Lyophilized hUSC-EX preserve the characteristics of exosomes and can improve chronically injured (8 weeks) ACL cells. Lyophilized hUSC-EX could serve as effective and safe biomaterials that are ready to use at room temperature to enhance cell activity in patients with partial ACL tears and after remnant preservation ACL reconstruction.
The invention discloses an oral liquid for preventing and treating intestinal diseases of livestock and poultry and a preparation method thereof, belonging to the technical field of veterinary drugs. Each 100 ml of the oral liquid contains the following effective components: 4.0 to 8.0 g of berberine hydrochloride, 90 to 96 ml of dandelion extract and 0.03 to 0.05 g of atropine. The dandelion extract is prepared through the following steps: soaking dandelion with water, carrying out heating reflux extraction twice, combining two liquid extracts, carrying out condensation, then adding 15 to 30 ml of a chitosan solution with a concentration of 0.5 to 2% into each 100 ml of a concentrate and successively carrying out flocculation for removal of impurities, centrifugation of a supernatant and condensation so as to obtain the dandelion extract. Each 1 ml of the dandelion extract is equal to 0.8 to 1.2 g of a crude drug. The oral liquid provided by the invention is a compound preparation of Chinese and western medicines; the dandelion extract, berberine hydrochloride and atropine are all used as pharmaceutical components, and through complex formulation of the Chinese and western medicines, the dandelion extract, berberine hydrochloride and atropine exert supplementary and synergistic effects to fully perform the advantages of the Chinese and western medicines; and the oral liquid has the efficacy of pain easing, inflammation diminishing, dysentery treating and the like. In use, each 100 ml of the oral liquid is mixed with 100 kg of water, livestock and poultry can be healed after taking the oral liquid for 2 to 3 days, and the advantages of a substantial effect and uneasy recurrence are obtained; and the oral liquid is applicable to exported chicken farms.
The remote electronically-delivered ICP (also known as eCARIBOU) will consist of psychiatry appointments through telemedicine every 4 weeks over 16 weeks, where the youth is at home. Prior to these appointments, measures (i.e., Mood and Feelings Questionnaire - MFQ) will be sent to the youth to be completed. Change in measure scores will be reviewed collaboratively between the psychiatrist and the youth to assist in making treatment decisions. The medication algorithm in the in-person ICP will be used to guide these decisions. The psychiatrist will also administer the Columbia Suicide Severity Rating Scale (C-SSRS) at each telepsychiatry appointment to monitor risk. Concurrently, youth will be offered internet-based Cognitive Behavioural Therapy (iCBT) and health-coaching via text.
PCT No. PCT/GB96/01580 Sec. 371 Date Jan. 6, 1998 Sec. 102(e) Date Jan. 6, 1998 PCT Filed Jul. 2, 1996 PCT Pub. No. WO97/02289 PCT Pub. Date Jan. 23, 1997Cyclic dimeric peptides of formula (I) wherein: peptide 1 and peptide 2 independently represent a tetrapeptide of formula -AA1-AA2-AA3-AA4- juxtaposed in parallel or antiparallel orientation; AA1 is an L or D amino acid selected from Ile, Leu and amino analogues thereof selected from Pro, Gly, Tic and Phe; AA2 is an L amino acid selected from Leu and amino acid analogues thereof selected from Ile, Phe and Val; AA3 is an L amino acid selected from Asp, Glu and amino acid analogues thereof; AA4 is an L amino acid selected from Val and amino acid analogues thereof selected from Leu, Ile, Phe and Cha (cyclohexylalanine); L1 and L2 independently represent linking moieties for linking peptides 1 and 2 to form a cyclic dipeptide; or salts thereof. The cyclic dipeptides inhibit the interaction of vascular cell adhesion molecule-1 and fibronectin with integrin very late antigen 4 and have therapeutic applications such as in rheumatoid arthritis, asthma or multiple sclerosis.
FIELD: medicine, pharmacy. SUBSTANCE: invention describes pharmaceutical composition consisting of mainly nevirapine semihydrate having diameter particles size about from 1 to 150 mc. The preparation is prepared by treatment of acid-additive nevirapine salt with strong base followed by filtration, washing out with water and drying up to water content about 3.1-3.9 weight % and water as carrier. Invention allows to obtain stable suspension of preparation. EFFECT: improved properties of preparation. 2 cl, 2 tbl, 3 ex
OBJECTIVE: Chromosome breakage is a catastrophic event that leads to the progressive development and progression of cancer. In order to analyze the changes of peripheral blood microenvironment of tumor patients, to explore the indicators of non-specific non-invasive tumor early screening. This paper presents a new idea of whether the gene sequence near the DNA damage break point is the gene sequence that controls the unrestricted growth of normal cells.
METHODS: The chromosomal aberrations of peripheral blood lymphocytes were analysed in 60 healthy adult and 49 cancer patients before radiotherapy.
RESULTS: The detection rate of chromosomal aberrations was high in tumor patients, and "dicentric + translocations" of chromosomes were detected in 36 patients (73.47 %). The chi-square test showed statistically significant differences (P < 0.01), and chromosome adhesion and dissolution were observed.
CONCLUSIONS: "Dicentric + Translocation" chromosome can be used as a nonspecific early screening indicator for cancer. This is worthy of further study. This index can be used to determine the genetic basis of various cancers at the gene level to modify the base sequence and prevent the occurrence of cancer. It is worthy of further study, and it can provide a new method for gene therapy of tumors.
A delayed timed release pharmaceutical composition, a preparation method therefor, and use thereof. The pharmaceutical composition comprises a tablet core. The tablet core comprises a drug-containing layer and a boosting layer stacked on the drug-containing layer. The drug-containing layer comprises a drug active ingredient. The drug active ingredient is levodopa or a derivative thereof, or a mixture of levodopa or a derivative thereof and a DOPA decarboxylase inhibitor, and accounts for 5-72.5 wt% of the content of the drug-containing layer. The pharmaceutical composition is a capsule-shaped tablet, can realize the effects of 1-3 h delayed release of the drug active ingredient and reaching a peak concentration at 6-10 h, can be used for reducing morning stiffness in patients with Parkinson's disease, and has good application prospects.